Equities research analysts predict that Ocular Therapeutix, Inc. (NASDAQ:OCUL) will post ($0.64) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ocular Therapeutix’s earnings. Ocular Therapeutix reported earnings of ($0.46) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 39.1%. The business is scheduled to announce its next quarterly earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Ocular Therapeutix will report full-year earnings of ($2.26) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.09). For the next financial year, analysts anticipate that the business will post earnings of ($2.55) per share, with EPS estimates ranging from ($3.00) to ($2.05). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.10. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.51 million. Ocular Therapeutix had a negative net margin of 2,620.06% and a negative return on equity of 80.26%. During the same quarter in the prior year, the business earned ($0.35) earnings per share.

OCUL has been the subject of several research reports. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Wednesday, March 22nd. BTIG Research lowered shares of Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research note on Friday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $35.00 price objective on shares of Ocular Therapeutix in a research report on Friday, May 5th. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. Finally, Morgan Stanley downgraded shares of Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price objective on the stock. in a research report on Friday, June 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Ocular Therapeutix currently has an average rating of “Hold” and a consensus target price of $21.55.

Several hedge funds have recently made changes to their positions in OCUL. Wellington Management Group LLP increased its stake in shares of Ocular Therapeutix by 35.2% in the first quarter. Wellington Management Group LLP now owns 1,312,703 shares of the biopharmaceutical company’s stock worth $12,182,000 after buying an additional 341,767 shares during the last quarter. Columbus Circle Investors increased its stake in shares of Ocular Therapeutix by 131.4% in the first quarter. Columbus Circle Investors now owns 1,087,605 shares of the biopharmaceutical company’s stock worth $10,093,000 after buying an additional 617,515 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Ocular Therapeutix by 24.0% in the first quarter. Vanguard Group Inc. now owns 902,262 shares of the biopharmaceutical company’s stock worth $8,373,000 after buying an additional 174,688 shares during the last quarter. Morgan Stanley increased its stake in shares of Ocular Therapeutix by 84.0% in the first quarter. Morgan Stanley now owns 604,636 shares of the biopharmaceutical company’s stock worth $5,611,000 after buying an additional 275,950 shares during the last quarter. Finally, Deltec Asset Management LLC increased its stake in shares of Ocular Therapeutix by 247.1% in the first quarter. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company’s stock worth $3,705,000 after buying an additional 284,200 shares during the last quarter. 65.25% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Analysts Expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to Announce -$0.64 Earnings Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/20/analysts-expect-ocular-therapeutix-inc-nasdaqocul-to-announce-0-64-earnings-per-share.html.

Ocular Therapeutix (NASDAQ:OCUL) opened at 6.59 on Thursday. Ocular Therapeutix has a one year low of $4.04 and a one year high of $11.91. The stock’s 50 day moving average is $9.51 and its 200-day moving average is $8.87. The firm’s market capitalization is $191.29 million.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.